ASCENDIS PHARMA A/S - AMERICAN DEPOSITARY SHARES

150,31

12-марта-25 16:45:00

15 мин. задержка

Акции

+4,68

+3,21%

Сегодняшний диапазон

146,35 - 150,61

ISIN

N/A

Источник

NASDAQ

Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults

11 сен 2024 17:37:50 Источник Nasdaq GlobeNewswire
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

03 сен 2024 17:06:29 Источник Nasdaq GlobeNewswire
Ascendis Pharma Reports Second Quarter 2024 Financial Results

03 сен 2024 17:04:32 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024

28 авг 2024 08:30:00 Источник Nasdaq GlobeNewswire
FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults

12 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

24 июн 2024 16:45:36 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

04 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

03 июн 2024 16:01:00 Источник Nasdaq GlobeNewswire
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

30 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

14 май 2024 14:31:44 Источник Nasdaq GlobeNewswire
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

13 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

09 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Reports First Quarter 2024 Financial Results

02 май 2024 16:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

25 апр 2024 16:46:31 Источник Nasdaq GlobeNewswire
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

24 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

04 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

07 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

31 янв 2024 16:15:00 Источник Nasdaq GlobeNewswire
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

31 янв 2024 16:01:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.